We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Allergy Therapeutics Plc | LSE:AGY | London | Ordinary Share | GB00B02LCQ05 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.00 | 2.80 | 3.20 | 3.00 | 3.00 | 3.00 | 0.00 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 59.59M | -43.07M | -0.0090 | -3.33 | 142.99M |
Date | Subject | Author | Discuss |
---|---|---|---|
26/6/2015 08:06 | It is truly nice to see confidence gaining in the AGY managements strategy, it was obviously evident when they raised £22million+ They just do not put a foot wrong in my eyes nor can they! Go for it AGY! | jimmyloser | |
25/6/2015 06:58 | At last the news we have been waiting for. Not sure what response we'll see in the share price today, but rest assured if these trials are successful then we're looking at several multiples of where we are now. I guess it depends how many people will invest based on US income potential as opposed to waiting until actual income. That said, lets not forget the Co is already profitable based on its Eu business which is growing..... | audigger | |
25/6/2015 06:05 | FANTASTIC Thank you AGY | jimmyloser | |
06/6/2015 20:59 | I too am puzzled. A few nuggets in there I thoughtIn addition to progressing our USA etc. progressingImmediate | jimmyloser | |
05/6/2015 10:53 | Interesting! Strange that the share price hasn't moved in response to this news.... | audigger | |
01/5/2015 07:14 | That appears to be that 600k overhang gone! impo. | jimmyloser | |
15/4/2015 16:15 | Could well be buys. Not much volume at the moment.Just sold my Persimmon holding today (nice eaner that was!) so may well top-up on these.....just trying to get the timing right, which usually I don't! | audigger | |
15/4/2015 14:15 | AuDigger It looks like sells at 19.65p now and buys at 20.3p Lots of nibble type buys going through Do you agree? | jimmyloser | |
14/4/2015 07:53 | Seems to have been a lot of low volume selling over the last week. Looks like its been walked down prior to what we hope is good news on the Phase III trial. | audigger | |
09/4/2015 12:23 | They did say that and I would expect an RNS as its key news. May be FDA are dragging their heels, not unknown! | audigger | |
09/4/2015 06:52 | AuDigger Didn't they indicate that they expected clearance for the trials from the FDA in mid March? Do you feel that they would have to RNS that news? jl | jimmyloser | |
09/4/2015 06:37 | All good stuff. Invesco almost doubled thier holding. Looking like the new placing has found several good homes. Is it time for the crawl back up to 30p? | audigger | |
09/4/2015 06:37 | All good stuff. Invesco almost doubled thier holding. Looking like the new placing has found several good homes. Is it time for the crawl back up to 30p? | audigger | |
07/4/2015 14:15 | Good post and appreciated. | jimmyloser | |
07/4/2015 13:36 | Allergy Therapeutics sees US breakthrough as route to global success By Ian Lyall April 07 2015, 2:03pm “We are at an inflexion point,” says chief executive Manuel Llobet.“We are at an inflexion point,” says chief executive Manuel Llobet. It came and went with little fanfare, but March 30 was a red letter day for Allergy Therapeutics (LON:AGY). A shareholder meeting signed off a £20mln share placing that will allow the company to take its Pollinex Quattro Grass product through to registration in 2019. If the product jumps through the final regulatory hoops (and analysts say it has a decent chance of success) then a US$2bn a year market beckons. The funding drives the company forward into new territory; but it does something else. It draws a line under the past – a difficult period that followed the US Food & Drug Administration&rsquo The worries, which centred on the adjuvant used to enhance the therapeutic impact of the drug, proved to be unfounded. However, it took five years to have the hold lifted on the clinical trial and a further four to get to this stage. “We are at an inflexion point,” says chief executive Manuel Llobet. “The immunotherapy business today is basically European, but it is going to become global very soon.” Pollinex is an injection that inoculates the patient against the irritating and some cases debilitating allergic reaction to grass pollen. Following in its wake are similar treatments for ragweed and tree pollen and, further down the line, dust mites. However, Pollinex Quattro Grass is the pathfinder. It will be the first subcutaneous (injectable) vaccine on the market in the US. And, if it is successful, it will be one of three or four clinically approved immunotherapies that offer lasting relief from allergies rather than simply treating the effects of allergic rhinitis (the catch-all term for the annoying inflammation of the nasal airways). While there are injectables in the US, there is no substantive clinical evidence the current crop work. “People are poorly served with primitive treatments and long courses of injections,” CEO Llobet explains. “We will bring a product to market that is an ultra-short course of vaccines with clinical evidence and standardisation. We think it will be a breakthrough in the US market.” First Pollinex must go through a phase III clinical trial that will assess efficacy prior to the drug being signed off by the US FDA. It is worth pointing out that U$100mln has been spent to date on the treatment, and was in the throes of carrying out a phase III study when development was halted. The FDA has asked Allergy’s researchers to use something called an environmental challenge chamber for its next clinical assessments for approval. It sounds medieval, but in very basic terms the challenge chamber is a room where the level of allergens is closely monitored. “With this you can really control the conditions,” says Llobet. “So you can be sure that patients are challenged properly with the amount of pollen – the measure of the efficacy is more accurate as you have the patients under controlled conditions. “It is good news to have this second phase-III in this form because I would say it is at less risk from the variability of the weather impacting on the pollen counts that occurs in the field.” Companies with a drug at this advanced stage normally seek outside help from a larger pharmaceuticals company ready to share the costs and the risks associated with this last stage of development. Conversations were had, but none of the firms Allergy’s team spoke to came up with the right financial solution that made a partnership worthwhile. It will reassess its alternatives once the regulatory process is out the way, but Llobet says he is keeping his and the firm’s options open. “It is not like we need a massive sales team. I’d say 50-60 reps would cover most of the [US] prescription universe. So if we don’t find the right partner we will go it alone,” the Allergy Therapeutics boss said. So far we have talked only about the US, where it is yet to make a sale. Yet in Europe, Allergy Therapeutics is a revenue-generating, profitable firm thanks to its Pollinex products, Acarovac for mite allergy, its penicillin diagnostic and treatments for wasp and bee stings. The interim results revealed the group generated revenues of just over £30mln and an operating profit of £7.5mln, up 13% on the year earlier. “The performance of all our products was good. They all grew 11% and did so across our main markets,” finance director Ian Postlethwaite reveals. The share price naturally came under pressure following the announcement of the placing on March 10 and the stock is trading at around 20p. Panmure Gordon in a note following the results on March 2 issued a target price of 33p and gave an upbeat assessment Allergy Therapeutics’ prospects. “The company continues to take market share from its competitors and despite exchange rate headwinds, the business is taking advantage of its product differentiation,&rdq | qackers | |
02/4/2015 06:35 | Odey in for 28 million. I wish I had 28 million of these! | audigger | |
31/3/2015 16:40 | Agreed. Y trades | jimmyloser | |
31/3/2015 16:18 | Loan notes converted today, placing shares on AIM tomorrow. Price action thereafter will be interesting! | audigger | |
31/3/2015 15:15 | What's happened? | aruntim | |
31/3/2015 14:54 | WE ARE DESPERATE FOR YOUR SHARES !!!! | jimmyloser | |
27/3/2015 17:30 | Interesting Y trades again today. The FDA has agreed in principle the synopses and is now reviewing the full protocol and statistical analysis to allow the clinical development to start; this permission is expected to be granted during March 2015.. RNS - Monday? Followed by result of extraordinary meeting? | jimmyloser | |
24/3/2015 22:55 | Double header of news expected within days. Look before you leap. | jimmyloser |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions